Besifloxacin in Bacterial Keratitis
Bacterial Keratitis
About this trial
This is an interventional treatment trial for Bacterial Keratitis focused on measuring keratits, besifloxacin
Eligibility Criteria
Inclusion Criteria:
• Provide signed and dated informed consent form
- Willing to comply with all study procedures and be available for the duration of the study
- Male or female, aged 18 or older
- Clinically diagnosed bacterial keratitis, with any size ulcer > 1mm.
Exclusion Criteria:
• Previously treated for current episode of bacterial keratitis with an antibiotic drop
- Corneal Ulcers <1mm
- Known allergic reaction to components of the study products
Sites / Locations
- McGill Academic Eye Center
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Group A: Besifloxacin
Group B: Fortified Antibiotics
Patients presenting with bacterial keratitis. These patients will be treated with besifloxacin ophthalmic suspesnion 0.6%, initially 6x a day and tapered down as the patient's condition improves based on the clinical judgement of the treating physician.
Patients presenting with bacterial keratitis. These patients will be treated initially with fortified cefazolin and vancomycin drops every 1 hour around the clock (24hours) for a minimum of 48 hours, and will subsequently have their dosages tapered gradually by the treating physician as is the standard of care for bacterial keratitis.